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Since cancer shares the same molecular machinery as the host, most therapeutic 
interventions that aim to target cancer would inadvertently also adversely affect the 
host. In addition, cancer continuously evolves, streamlining its host-derived genome 
for a new single-celled existence. In particular, short-term clinical success observed 
with most antineoplastic therapies directly relate to the fact that cancer is constantly 
evolving. However, the clonal evolution of cancer occasionally also render cancer 
cells uniquely susceptible to therapeutic interventions, as is exemplified by the clinical 
relevance of synthetic lethality. Synthetic lethality describes a situation where the 
simultaneous loss of function in two genes results in lethality, but where a loss of 
function in either single gene is tolerated. This observation suggests that the evolution 
of cancer, usually seen as a major clinical challenge, may also afford a key oppor-
tunity in lowering on-target toxicities accosted with chemotherapy. As an example, 
by subjecting cancer to specific selection regimes, cancer can in effect be placed 
on evolutionary trajectories leading to the development of “targetable” phenotypes 
such as synthetic lethal interactions. However, such a selection regime would have 
to overcome a range of obstacles such as on-target toxicity and the selection of an 
evolvable trait. Since the majority of cancer evolution manifests as a loss of function, 
we suggest that the induction of auxotrophic phenotypes (i.e., where an organism 
lose the ability to synthesize specific organic compounds required for growth and thus 
become dependent on it from dietary sources) may represent an attractive therapeu-
tic option. As an example, animals can obtain vitamin C either by de novo synthesis 
or from their diet. However, since the maintenance of synthetic pathways is costly, 
such pathways are often lost if no longer necessary, resulting in the organism being 
auxotrophic toward the dietary compound. Similarly, increasing the maintenance cost 
of a redundant pathway in cancer cells is likely to select for clones that have lost 
such a redundant pathway. Inhibition of a pathway, while supporting the activity of 
a compensating pathway, may thus induce auxotrophism in cancer cells but not in 
genomic stable host cells.
Keywords: synthetic lethality, auxotrophy, cancer, evolution, chemoresistance
Abbreviations: AIR, auxotrophic induction regime.
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introdUCtion
The fact that cancer is derived from the host’s own tissue possess 
a major challenge for the development of effective therapies. 
Since cancer shares the same molecular machinery as host, most 
therapeutic interventions aimed at targeting cancer would inad-
vertently also adversely affect the host tissue. Indeed, the small 
therapeutic window of most chemotherapeutic agents directly 
relates to the on-target toxicity associated with chemotherapy. 
The problem is compounded by the fact that the host represents 
a complex system of interdependent organs and tissues systems. 
Consequently, patient tolerance toward therapeutic agents is usu-
ally limited by the tissue exhibiting greatest sensitivity toward the 
chemotherapeutic intervention. The evolvability of cancer repre-
sents another clinical challenge. In a few cases, targeted therapy 
induces cancer remission with comparatively little side effects. 
Yet, it has been noted that such therapies successes are usually 
short lived and only extend survival by a few months in advanced 
cancer (1). Indeed, in most cases, therapeutic intervention often 
results in a significant decline in tumor size only for cancer to 
re-emerge as chemo-resistant strains (2–5). Thus, the fact that 
cancer shares the same cellular mechanism and components as 
the host, in conjunction with the evolvability of cancer, remains a 
major challenge in the development of a cure for cancer.
Thus, these challenges explain why, despite the tremendous 
advances made in understanding the biology of cancer, in the 
majority of cases, we have not won the war on cancer yet (6). 
Accordingly, some have proposed that we rethink the problem 
of cancer in an attempt to develop novel therapeutic interven-
tions (7). In this regard, the application of ecological principals 
in managing cancer has similarly gained much attention (8–11). 
Indeed, many concepts used to describe ecological interactions 
are easily transferable to an oncological context. As an example, 
predation (immune surveillance), niche construction (tumor 
micro-environment), and concepts such as fitness (proliferative 
potential of cancer cells in a given environment) all encompass 
cancer relevant traits (9). Furthermore, an ecological perspective 
addresses the evolvability of cancer. As an example, it has been 
pointed out that under certain conditions, chemoresistance to one 
compound may result from a set of mutations that render cancer 
cells “collateral sensitive” toward another agent (12). Similarly, 
instead of aggressively applying therapies aimed at completely 
eradicating cancer, low-dose chemotherapy aimed at reducing 
tumor load while sparing chemosensitive cancer cells may hold 
an advantage as these cells compete with drug-resistant strains, 
thus limiting the growth of these strains (11). An ecooncological 
view thus opens novel therapeutic strategies to the challenges 
posed by drug resistance.
Although these “ecology-based” therapies address the evolu-
tion of cancer, we suggest that cancer evolution may also provide 
clinical opportunities. In particular, carefully chosen selective 
pressures could potentially be used to direct the evolution of traits 
that render cancer cells more sensitive to the subsequent thera-
peutic interventions, thus lowering on-target toxicity. However, 
the evolution of cancer cells differs in a number of key aspects 
from evolutionary processes associated with other organisms, 
presenting opportunities, as well as challenges in directing the 
evolution of cancer. These issues are briefly reviewed after which 
we outline a hypothetical approach for directing the evolution of 
cancer cells.
CanCer eVoLUtion
Cancer cell heterogeneity has emerged as a key factor in the 
development of chemo-resistance (13, 14). Tumor hetero-
geneity results not only from phenotypic plasticity (15) but 
also arises due to the numerous mutations that drive the 
evolution of drug resistance (16). Indeed, it has been argued 
that the astonishing number of mutations observed in many 
tumors (2, 16–19) cannot be explained by normal background 
mutational rate and that certain cancers possess a “mutator 
phenotype” (20, 21). Mechanistically, an elevated rate of muta-
tions observed in cancer cells may relate to increasing ane-
uploidy (22) and to alterations in the DNA damage response, 
which decrease the ability of cancer cells to correct DNA 
damage (23). In addition, various chemotherapeutic agents 
are mutagenic (24), thus potentially enhancing the mutation 
rate. Furthermore, the ability of cancer to evolve (e.g., exhibit a 
mutator phenotype) might be more than an accidental trait: 
both theoretical models and simple single-cell systems have 
demonstrated that, in an environment that is rapidly chang-
ing, the ability to evolve may itself be a trait under Darwinian 
selection (25). Since chemotherapy represents a major shift 
in the tumor “ecosystem,” therapeutic interventions may in 
fact select for an “evolvable” phenotype. These observations 
thus explain the highly evolvable nature of cancer cells that 
invariably lead to the development of drug resistance.
The clonal evolution of cancer cells differs from typical evolu-
tionary processes in several ways. First, since cancer arises with 
most of the host genome intact, cancer cells are pre-equipped 
with various genomic protocols for subverting host systems. This 
is exemplified by the observation that tumors typically re-enact 
a transcriptional profile observed during wound healing (26). 
Similarly, invasive cancer cells re-enact transcriptional profiles 
associated with placentation (27, 28). These observations dem-
onstrate how cancer evolve not only by the generation of novel 
functionalities but also by “rediscovering” pre-existing genomic 
content usually not activated in untransformed tissue. In addition, 
the evolution of cancer is also constrained in certain unique ways. 
As an example, the fact that cancer only persists within the life 
span of the patient limit the range of phenotypes, which can be 
selected for (14, 29). Furthermore, cancer cells reproduce asexual 
and exhibit a very high mutation rate with genomic instability, 
and most of the mutations tend to involve a loss of gene function, 
rather than the evolution of novel gene functions. In addition, 
there is a bias in the kind of genes that are most often mutated 
(e.g., loss of pro-apoptotic proteins such as p53). In fact, it has 
also become apparent that not all genes are equally evolvable: in 
cancer, inactive genes tend to exhibit a higher mutation burden, 
probably as a result of reduced transcription-coupled repair pro-
cesses (30). Collectively, these observations suggest that cancer 
is highly evolvable, but that the mechanism underlying cancer 
evolution is distinct and largely associated with the exploitation 
and rediscovering of a pre-existing genome.
FiGUre 1 | Synthetic lethality. Two circuits, which may represent variably 
functions such as biosynthetic pathways or cellular functions such as 
genomic repair mechanisms, are synthetically lethal if viability is maintained 
despite the loss of either single circuits [(B) or (C)], but not both (d).
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eXpLoitinG Loss oF FUnCtion: 
syntHetiC LetHaLity
The evolution of cancer also leads to the development of 
genomic dependencies that render cancer cells more vulner-
able to therapeutic intervention, a situation well exemplified 
by synthetic lethality. Consider a system that consists of two 
effector pathways circuit A and B within a cell, which operates 
independent of each other, in a manner that render them func-
tionally redundant (Figure 1). As an example, A may represent 
a mechanism to import a factor required (e.g., an amino acid 
transporter), whereas B represents a pathway associated with 
the de novo synthesis of a required factor (e.g., synthesis of an 
amino acid). If both circuits are operational (Figure 1A), cells are 
viable. Similarly, if A is defective (Figure 1B), B can compensate, 
thus ensuring cell survival. Conversely, despite inactivation of 
B, cells remain viable as a result of the compensatory effect of 
A (Figure  1C). If, however, both A and B are inactivated, cell 
viability is compromised (Figure 1D). In such a system, A and B 
are synthetically lethal, since a loss of either A or B is tolerated, 
whereas the simultaneous loss of both A and B are not.
Synthetic lethality can be employed to elucidate the role of genes 
and map gene–gene interactions and has also gained interest in 
context of cancer therapy (31, 32). As an example, CRISPR-based 
screens of cancer cells have been used to identify synthetic lethal 
interactions between genes, thus exposing potential therapeutic 
targets, and has also revealed the functions of previously unchar-
acterized proteins (33). In fact, synthetic lethality interactions 
have also been shown to be of clinical relevance: cancer cells bear-
ing mutations in BRCA1 or BRCA2, which play a key role in the 
repair of double-strand DNA breaks, are susceptible to inhibitors 
of the enzyme poly ADP ribose polymerase, which also plays a 
role in repairing DNA lesions (34).
The implementation of synthetic lethality within an oncologi-
cal context is dependent on the ability of cancer cells to evolve. 
In particular, the loss of function renders cancer cells dependent 
on compensatory genes. Although synthetic lethality has thus 
far been opportunistically exploited, we argue that cancer cells 
might be placed on evolutionary trajectories that would select for 
functional dependencies similar to synthetic lethality. However, 
a selection regime should exhibit certain properties. First, the 
evolution of a synthetically lethal phenotype must be an evolv-
able trait and also be responsive toward a clinically applied 
evolutionary pressure. Second, the selection regime used to direct 
the evolution of a synthetically lethal phenotype should be well 
tolerated and not be associated with severe side effects. Here, it is 
argued that the induction of an auxotrophic phenotype might be 
ideal, as such an approach can fulfill these requirements.
aUXotropHisM as a ForM  
oF syntHetiC LetHaLity
Auxotrophy refers to the reliance of an organism on a biological 
compound for appropriate growth and development, but which 
cannot be synthesized by the organism itself. As an example, 
many vertebrates possess both effective mechanisms for acquir-
ing ascorbic acid (vitamin C) from the diet and pathways for its 
de  novo synthesis. In contrast, certain animals (e.g., humans, 
guinea pigs, certain bats and fish) have lost this ability to synthesize 
ascorbic acid—these animals exhibit vitamin C auxotrophy. The 
independent loss of capacity to synthesize vitamin C in numer-
ous species with a diet high in vitamin C (35) may be explained 
by the fact that hydrogen peroxide formation during vitamin C 
synthesis (36) represents a cost for maintaining this pathway. In 
animals consuming a diet rich in vitamin C, the loss of biosyn-
thetic capacity thus would be advantageous, thus explaining the 
loss of synthetic capacity in such animals (37).
Evidence suggests that cancer cells may similarly evolve 
auxotrophic phenotypes. As an example, certain cancers exhibit 
auxotrophy toward arginine as a result of reduced expression 
of argininosuccinate synthase (38, 39). In these cancerous cells, 
prolonged arginine starvation induces a form of autophagic cell 
death (40). In fact, recent results from a phase II multicenter 
randomized clinical trial demonstrated that arginine deprivation 
with pegylated arginine deaminase increased the progression-free 
survival of cancer patients (41). Similarly, Kung et al. (42) recently 
described a small molecule activator for PKM2 that results in the 
shunting of glycolytic intermediates away from serine biosynthe-
sis pathways, rendering cancer cells auxotrophic toward serine. 
This demonstrates that auxotrophism may represent an evolvable 
trait in cancer cells.
Importantly, although auxotrophism is usually described 
with regards to metabolic substrates, the same concept may be 
applied to signaling molecules. As an example, the growth pro-
moting effect of estrogen on estrogen receptor-positive tumors, 
as well as the “oncogene addiction” exhibited by some cancers 
(43) may be seen as a form of “tropism” where a signal instead 
of a metabolite is required for normal growth. These circuits 
(metabolic pathways or cell signaling cascades) may also over-
lap. As an example, the proto-oncogene c-Myc not only plays an 
important role in activating mitogenic signals but also plays an 
important role in shifting the metabolism of cancer cells toward 
aerobic glycolysis (44).
FiGUre 3 | Auxotrophism can be artificially induced. Two pathways, Circuit A and Circuit B, which operate independent and redundant of each other, are 
dependent on auxotrophic factors (e.g., signaling molecules or metabolic substrates). By removing the substrate (B) or administering Circuit A blockers (a), a cell 
become auxotrophic toward auxotrophic factors for Circuit B (C).
FiGUre 2 | An auxotrophic system exhibits traits associated with synthetic 
lethality. Two pathways, Circuit A and Circuit B that operate independent and 
redundantly of each other, are dependent on auxotrophic factors (e.g., 
signaling molecule or metabolic substrate).
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Induction of an auxotrophic phenotype can, if two circuits 
(e.g., metabolic pathways or signaling cascades) are redundant 
(i.e., once circuit could compensate for the loss of another), 
exhibit traits similar to synthetic lethality (Figure 2). As an exam-
ple, losing the ability to synthesize a metabolite would render 
cells synthetically lethal toward the inhibition of a transporter 
(or withdrawal of auxotrophic factor). Similar to the descrip-
tion provided to synthetically lethal genes, two circuits A and B 
(Figure 2) can be considered where the inactivation of one or the 
other, but not both simultaneously, remains viable. Thus, evolu-
tion of an auxotrophic phenotype can occasionally represent as a 
form of synthetic lethality.
indUCtion oF aUXotropHiC 
pHenotypes
An auxotrophic system with synthetic lethal attributes exhibits 
two unique properties (Figure 3). First, the value of maintaining 
a circuit (either A or, B, or both) can be controlled by rendering a 
circuit inoperable and thus remove the incentive for maintaining 
the circuit. As an example, either blocking the receptor/trans-
porter (Figure  3A) or withdrawal of the auxotrophic factor 
(Figure  3B) would render the circuit non-functional and thus 
dispensable. Second, an auxotrophic system provides the oppor-
tunity to introduce “rescue therapy”: inactivation of one circuit 
may be compensated for by supplying an auxotrophic substrate 
for the compensating circuit (Figure 3C).
Such a hypothetical system represents a prime target for 
inducing an auxotrophic dependency in cancer cells. First, the 
selection regime is inducible by either limiting the auxotrophic 
factor (Figure 3B) or through the implementation of inhibitors 
(Figure  3A) (e.g., blocking a signaling cascade or limiting the 
import of a metabolic substrate). Since the circuit inhibited is of 
no value, loss of function mutation can occur without out loss of 
viability. Indeed, if maintenance of the inhibited circuit is associ-
ated with a cost, such a trait is more likely to be lost. Second, since 
circuits are redundant, on-target toxicity should be minimal and 
can theoretically be further decreased by the administration of 
“rescue therapy”—auxotrophic substrate utilized by the compen-
sating circuit (Figure 3C).
As a clinical application, i.e., where both host and cancer are 
subjected to the same intervention, the two-step approach will 
result in a therapeutic target unique to cancer cells (Figure 4). 
First, the initiation of an auxotrophic induction regime (AIR) is 
introduced (Figures 4A,B), with the goal of directing the evolu-
tion of auxotrophism in cancer cells. This is followed by therapeu-
tic intervention, directed at targeting auxotrophic dependency in 
cancer cells (Figure 4C). The AIR consists of blocking circuit A, 
while simultaneously administering rescue therapy in the form of 
an additional auxotrophic substrate to compensate for Circuit B 
(Figure 4A). The inhibition of A would result in a viable pheno-
type as B can compensate for an inoperable A. That is, assuming 
perfect redundancy between A and B, both host and cancer cells 
would be viable under these conditions. However, since inhibi-
tion of Circuit A would render the circuit redundant, a mutation 
that knockout A in a cancer cell may benefit cancer cells if main-
tenance of A decrease replication efficiency (Figure 4C). Thus, a 
sub-clone of cancer cells that do not invest in the “contextually 
FiGUre 4 | Evolutionary procedure for auxotrophic induction in cancer cells provides differential targets. Auxotrophy in cancer cells toward B is induced by 
simultaneously administering an inhibitor of A and an auxotrophic substrate for circuit B as rescue therapy (a,B). Since maintenance of contextually useless circuits 
are expensive, cancer cell losing A would have a fitness advantage above cells maintaining A. Thus, sub-clones auxotrophically dependent on B would dominate. 
An intervention challenge would consist of inverting the “poison” and “antidote” regime (C): inhibition of Circuit B while upregulating flux through Circuit A with an 
additional auxotrophic substrate. Mutated cancer cells are unresponsive to rescue by the auxotrophic substrate for A as a result in loss of function in circuit A.  
Thus, cancer cells no longer have a functioning circuit, resulting in cell death.
5
van Niekerk et al. Evolutionary Strategies in the War on Cancer
Frontiers in Oncology | www.frontiersin.org December 2017 | Volume 7 | Article 304
useless” A, but rather invest in B, would have an evolutionary 
advantage over cells that maintain A. However, such a beneficial 
mutation would render cells auxotrophic toward the substrate 
required to maintain circuit B (i.e., render cells dependent on 
auxotrophic substrate for circuit B). Following the induction of 
an autotropic phenotype, intervention therapy can now be imple-
mented (Figure 4C) to exploit this auxotrophic dependency: by 
now inhibiting B, but administering rescue therapy in the form 
of a compensatory auxotrophic substrate for circuit A, host cells 
can compensate and remain viable. In contrast, cancer cells, now 
lacking a compensatory circuit A, are no longer viable.
In this manner, the evolvability of cancer cells can be turned 
against themselves: these “evolutionary successful” cells that 
lack circuit A are now auxotrophic toward substrate required 
for system B. Note that, because A and B are redundant, on-
target toxicity to host and cancer cells would be minimum 
under the AIR. After AIR, intervention therapy can be initiated, 
by blocking B, while administering additional substrate for A 
(i.e., swapping the “poison” and “antidote” used in the AIR 
regime). Since host cells are genomically stable, these cells can 
reactivate A and remain viable despite B being pharmacologi-
cally knocked-out.
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FUtUre CHaLLenGes
Biological systems are likely to exhibit various circuits (cell 
signaling cascades or metabolic pathways). Indeed, degeneracy, 
a “ubiquitous biological property” refers to the ability of a bio-
logical system to enact the same phenotype through different 
mechanisms (45). Thus, it is likely that various synthetically 
lethal circuits may be operating in cells, with the potential for 
auxotrophic induction. In addition, viewing signaling molecules 
as auxotrophic factors may widen the range of potential targets. 
Of key importance, however, would be to identify a candidate 
system that is costly to maintain: the higher the maintenance 
cost, the greater the evolutionary incentive to disinvest in the 
particular circuit (i.e., lose functionality). Also, if auxotrophic 
factors are secreted by other cells, it would render substrate/
signaling withdrawal impossible. Alternately, serum levels of 
secreted auxotrophic targets would need to be reduced by admin-
istering enzymes capable of metabolizing these compounds or 
be inactivated/removed by chelators. Most likely, inhibitors or 
transporters could prove most useful.
Signaling pathways pose an additional challenge for auxo-
trophic induction, since cancer cells are more likely to evolve 
independence from exogenous signals (e.g., mutation of genes 
resulting in constitutively activated proteins). None the less, tar-
geting signaling pathways may augment auxotrophic phenotypes 
since metabolic and signaling circuits are often intimately linked. 
As an example, Kras driver mutations regulate the metabolic 
reprogramming in pancreatic tumors (46). Similarly, activated 
EGFR induces translocation of PKM2 into the nucleus where 
it interacts with other transcription factors promoting tumor 
growth (47). HIF-1 also upregulates PKM2, while PKM2 acts as 
a cofactor of HIF-1, thus modulating its transcriptional activ-
ity (48). Collectively, these observations suggest that targeting 
signaling and metabolic circuits may provide synergistic effects 
in placing cancer cells on evolutionary trajectories. Alternatively, 
the set of oncogenic signaling profiles might highlight putative 
metabolic pathways, which might be best to target, as the signal-
ing pathways might dictate the metabolic dependency of the cell.
An additional requirement for auxotrophic induction is that 
the redundancy in circuits must be substantial to allow for effective 
compensation by alternative pathways, thus minimize on-target 
toxicity. The requirement of redundancy is of particular impor-
tance as evolutionary therapies are likely to be implemented over 
an extended period of time. Also, evolutionary pressures select 
for phenotypes. Since a similar phenotype can be induced by 
various means, great care must be taken to ensure that the given 
selective regimes would result in the desired set of mutations. In 
this regard, network analysis of metabolic/signaling pathways 
may assist in identifying targetable circuits. Furthermore, it might 
be useful to target genes that are more likely to mutate, as it has 
been noted that regional mutation rates are not constant across 
the genomes of cancer cells (49). In particular, somatic mutation 
rates are highest in inaccessible, heterochromatin-like regions 
with low gene expression (49). This suggests that inactivated 
genes are more likely to undergo random mutations.
Another key challenge relate to the fact that cancer consists of 
heterogeneous populations of cells bearing different mutational 
profiles and, as such, are likely to respond differently to a particu-
lar selective pressure. Thus, it is exceedingly likely that all cells will 
evolve a targetable auxotrophic phenotype. Indeed, therapeutic 
failure, seen with conventional as well as with targeted therapy, 
suggests this is to be expected. Here, similar to current clinical 
practice with conventional therapeutic regimes, combination 
therapy can be implemented: cells can be placed on various 
selection regimes to induce multiple auxotrophisms simultane-
ously to maximize the possibility to target most cells. Similarly, 
“second-line auxotrophism selection” may be initiated as sequen-
tial therapy. In fact, because AIRs exhibit the potential to have 
reduced toxicities, it is possible that sequential cycling through 
various AIRs may be well tolerated for prolonged periods, result-
ing in a novel form of maintenance therapy.
It also remains to be established if the evolution of cancer 
takes place within a feasible time window. Cancer often evolves 
resistance to different therapeutic interventions within a matter 
of months, suggesting that the evolution of cancer can be rapid. 
However, although chemotherapy represents a very strong 
selective pressure, it is not obvious whether cancer cells can be 
subjected to a strong enough selection regime to similarly evolve 
an auxotrophic phenotype within a realistic time window. These 
considerations also suggest that certain cancers, such as those 
exhibiting a mutator phenotype, may be more amenable to this 
strategy. Also, evolution of an auxotrophic phenotype is much 
more likely if an auxotrophic clone exhibits a competitive advan-
tage over non-auxotrophic clones. As an example, if inhibition of 
a metabolic pathway results in the buildup of a potentially toxic 
metabolic intermediate, auxotrophic clones that do not invest in 
the metabolic pathway (i.e., lack the biosynthetic ability) would 
have a competitive advantage since they would avoid accumulat-
ing toxic intermediates. An example of such a process is the loss 
of vitamin C synthesis in animals that acquire sufficient amounts 
of vitamin C through their diet, which is argued to develop, since 
loss of synthetic capacity would avoid the generation of hydro-
gen peroxide, which occurs during vitamin C synthesis (36). In 
addition, many patients enter remission for years after initial 
chemotherapy. However, the sad reality is that for many of these 
patients, tumors do reoccur. Here, since an AIR may have very 
low toxicity, incorporating a prophylactic induction regimes in 
the survivorship care plan may be beneficial: therefore, if cancer 
is predestined to re-emerge, the cancer cells will expand under 
a pre-existing selective pressure. This would have the effect of a 
“population bottle-neck” and also extend the time period under 
which cancer cells are subjected to selective pressures. This would 
enhance the likelihood of cancer evolving an auxotrophic pheno-
type within a realistic time frame.
Another key question not addressed is which particular 
molecular circuits should be targeted and can these circuits be 
targeted with minimum toxicity. Also, can the evolution of cancer 
be effectively predicted? Here, as proof of concept, initial studies 
may subject cells to a selection regime to induce an auxotrophism 
in  vitro. The “evolved” (i.e., auxotrophic) cancer cells can then 
be injected into a mouse model, and the intervention therapy be 
applied to test the efficacy of the selection regime. It may also 
be useful to investigate how evolution of a phenotype manifests. 
In this regard, genotyping cancer cells under selection for an 
FiGUre 5 | Mapping the stepwise mutational development of auxotrophic phenotypes. In vitro selection regimes may result in the development of auxotrophic 
phenotypes. Mapping the stepwise genomic changes may provide insight into the evolutionary steps that induce an auxotrophic phenotype.
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auxotrophic phenotype may be instructive: successfully mapping 
the genomic alteration that drive the auxotrophic phenotype may 
be valuable in developing models that predict the evolution of 
cancer cells to refine the selection regimes (Figure 5). A subse-
quent step may include exploring the feasibility of this approach 
in companion animals in comparative oncology trials (50). Here, 
the clinical application of auxotrophic phenotypes (under auxo-
trophic regimes that exhibit minimum toxicity) may be applied 
concurrently with standard therapy, or as mentioned, initiated 
during remission to test the feasibility of this hypothesis in a more 
realistic setting before applying the therapy in humans.
ConCLUsion
The low toxicity of this approach may suggest that auxotrophic 
induction can provide effective adjuvant therapy. In settings 
where curative therapy is no longer realistic, cycling through dif-
ferent evolutionary regimes (i.e., inducing various auxotrophisms 
sequentially) may provide a novel form of maintenance therapy. 
We also suspect that phenotypes other than synthetic lethality 
could be selected for in cancer. As an example, cancer cells could 
be selected for a less noxious phenotype.
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